- Home
- LIDR vs RLYB Comparison
LIDR vs RLYB Comparison
Compare LIDR & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDR
- RLYB
- Stock Information
- Founded
- LIDR 2013
- RLYB 2018
- Country
- LIDR United States
- RLYB United States
- Employees
- LIDR N/A
- RLYB N/A
- Industry
- LIDR Auto Parts:O.E.M.
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- LIDR Consumer Discretionary
- RLYB Health Care
- Exchange
- LIDR Nasdaq
- RLYB Nasdaq
- Market Cap
- LIDR 14.8M
- RLYB 14.4M
- IPO Year
- LIDR N/A
- RLYB 2021
- Fundamental
- Price
- LIDR $0.92
- RLYB $0.35
- Analyst Decision
- LIDR Hold
- RLYB Hold
- Analyst Count
- LIDR 1
- RLYB 3
- Target Price
- LIDR N/A
- RLYB $15.00
- AVG Volume (30 Days)
- LIDR 577.6K
- RLYB 323.9K
- Earning Date
- LIDR 08-04-2025
- RLYB 08-07-2025
- Dividend Yield
- LIDR N/A
- RLYB N/A
- EPS Growth
- LIDR N/A
- RLYB N/A
- EPS
- LIDR N/A
- RLYB N/A
- Revenue
- LIDR $246,000.00
- RLYB $848,000.00
- Revenue This Year
- LIDR $2,677.23
- RLYB N/A
- Revenue Next Year
- LIDR $409.09
- RLYB N/A
- P/E Ratio
- LIDR N/A
- RLYB N/A
- Revenue Growth
- LIDR N/A
- RLYB N/A
- 52 Week Low
- LIDR $0.49
- RLYB $0.22
- 52 Week High
- LIDR $4.30
- RLYB $1.54
- Technical
- Relative Strength Index (RSI)
- LIDR 65.47
- RLYB 53.64
- Support Level
- LIDR $0.71
- RLYB $0.30
- Resistance Level
- LIDR $0.88
- RLYB $0.38
- Average True Range (ATR)
- LIDR 0.09
- RLYB 0.04
- MACD
- LIDR 0.00
- RLYB 0.00
- Stochastic Oscillator
- LIDR 89.21
- RLYB 49.29
About LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.